Bioinformatics
No bosses here

By integrating multiple layers of high-throughput data with a strong knowledge of tumor biology we build hypotheses that can be tested using molecular biology methods. We are continuously developing and improving methods for analysis of deregulated signaling pathways in cancer by merging mutational, copy-number, gene expression, and quantitative proteomics data....

Plasma proteomics
Maria Pernemalm

Being able to monitor these biomarkers by a simple blood test is in many cases the ultimate goal. The overall aim for the plasma proteomics team is to develop an accurate and sensitive pipeline for mass spectrometry based analysis of the plasma proteome. Due to the skewed protein concentration distribution...

Lung cancer
Lukas Orre

Our general aim is to identify novel biomarkers and targets for cancer therapy to improve the treatment of non-small cell lung cancer (NSCLC). To accomplish this we are developing and applying advanced methods to study the effects of cancer therapy. We are specifically interested in therapies targeting receptor tyrosine kinases...

Breast cancer
Henrik Johansson

Our overall aim in the BC team is to use MS based proteomics tools to increase our biological understanding of breast cancer, define clinical subtypes, and identify biomarkers for personalized therapy. The estrogen and progesterone receptors are routinely used together with the tyrosine kinase receptor HER2 to stratify breast cancer...

Proteomics methods
Rui Branca

In our group, we are developing and applying mass spectrometry (MS)-based methods with an aim to improve human proteome analysis. We have developed a prefractionation method known as high-resolution peptide isoelectric focusing (HiRIEF) (Branca, Nature Methods 2014). This method allows reproducible fractionation leading to a reduction of sample complexity prior...

Childhood cancer
Rozbeh Jafari

Our overall aim in the Childhood Cancer team is to use mass spectrometry based proteomics to increase our biological understanding of Acute Lymphoblastic Leukemia (ALL) and Neuroblastoma, define clinical subtypes, evaluate drug interactions and identify biomarkers for targeted thereapies, improving personalized therapy. Childhood ALL is the most common pediatric cancer...